Can a Two-Drug combo tip the scales against obesity?

NCT ID NCT07765511

Not yet recruiting Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This early-stage trial is testing whether a new drug called macupatide, given alone or with another drug called eloralintide, is safe and well-tolerated in Japanese adults with obesity or overweight who do not have type 2 diabetes. Participants will receive multiple doses and stay at a research unit for monitoring. The study also looks at how the drugs move through the body and whether they affect body weight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Macupatide (alone and in combination with eloralintide), given as injections
What this could lead to: If successful, this could support the development of a new combination treatment for obesity, potentially offering better weight loss options.
What could go wrong: This is an early-phase trial focused on safety and dosing, not proof of effectiveness. Side effects are possible, and the results may not lead to a marketable treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic

Toshima City, 171-0014, Japan
Souseikai Fukuoka Mirai Hospital

Fukuoka, 813-0017, Japan
Sumida Hospital

Sumida-ku, 130-0004, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.